About

About GLP-1 Nutrition

GLP-1 Nutrition is an independent clinical resource on nutrition during therapy with GLP-1 receptor agonist medications: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and exenatide (Bydureon, Byetta). The site exists because the existing public-facing content on GLP-1 nutrition is dominated by drug-vendor marketing, telehealth-startup landing pages, and generic weight-loss copy — none of which addresses the actual physiology of these medications or the practical eating challenges patients face when their appetite is suppressed and their body composition is changing rapidly.

Audience

The primary audience is people prescribed a GLP-1 receptor agonist for Type 2 diabetes or for chronic weight management, and the dietitians and clinicians who care for them. Family members supporting a patient on these medications are a frequent secondary audience, particularly for the side-effect-management content.

Editorial team

The site is led by Priya Krishnan, MD, ABOM (board-certified obesity-medicine physician, editor-in-chief). Clinical content is written by Hannah Ekberg, MS, RD, CDCES (lead dietitian, body-composition under pharmacotherapy) and Marcus Adeyemi, RD (practical cooking and side-effect-management content). Every clinical guidance article is reviewed and signed off by Jonathan Park, MD, FACE (board-certified endocrinologist, medical reviewer) before publication.

Methodology

All clinical claims are sourced to the published literature and labeled with citations to real, peer-reviewed journals (NEJM, The Lancet, Obesity, JCEM, Diabetes Care, Obesity Reviews) or to published society guidelines (ADA Standards of Care, AACE/Endocrine Society Obesity Algorithm). Where the evidence base is thin or contested, the article hedges. Numeric recommendations (e.g., starting protein targets) are presented as ranges with explicit caveats. No article on this site offers a specific dose, titration schedule, or instruction to start, stop, or change a medication; those are clinician decisions.

App reviews

App reviews are scored on fit-for-GLP-1 across four axes: photo-logging speed when meals are small, protein-tracking depth, micronutrient coverage under reduced intake, and presence (or absence) of a built-in GLP-1 workflow. Reviewers do not accept payment, sponsorship, or affiliate revenue from any reviewed app developer. App testing is performed on the editorial team's own devices and accounts, paid for from editorial budget.

Conflict of interest

GLP-1 Nutrition does not accept any of the following: payment from medication manufacturers; payment from app developers; payment from supplement brands; affiliate revenue on any link, anywhere on the site; sponsored content of any kind; advertising. The site's operating costs are funded by the founder. Any future material change to this policy will be disclosed on this page and on the editorial-policy page.

Corrections

Errors of fact will be corrected as soon as identified, with a visible correction notice on the affected page describing what changed and when. Substantive scientific updates (e.g., a new society guideline supersedes a recommendation here) trigger a full editorial review and a refreshed "last reviewed" date.